Phase 3Completed
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
A Single-blind, Single-treatment Study to Evaluate the Effects of Vildagliptin on Response to an Intravenous Glucose Load in Pre-diabetic Subjects With Impaired Fasting Glucose
- Sponsor
- Novartis (Industry)
- Enrollment
- 20 planned
- Conditions
- Pre-diabetes
- Interventions
- Vildagliptin
- Ages
- adults, older adults
- Registry
- NCT00312130
Full record on ClinicalTrials.gov
From the registry
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
Primary outcomes
- Change from baseline in acute insulin response to an iv glucose load at 6 weeks
History
Last registry update
Primary completion
Registered
Started